Insulin-like growth factor 1 comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-07-23. Where a claim depends on a specific study, the study is described rather than over-claimed.
Whether the drug improves hard clinical outcomes is not settled. No completed trial has shown a reduction in heart attacks or strokes among treated patients, although a dedicated cardiovascular outcomes study has been discussed in the literature. Investigators have also examined hepatic fat in people with HIV and fatty liver disease, cognitive measures in small cohorts, and changes in bone density. Regulatory labeling emphasizes monitoring of insulin-like growth factor 1 because supraphysiologic levels raise questions about tissue growth, and the clinical significance of that signal remains an open question rather than a demonstrated harm.
Binding of tesamorelin to the growth hormone-releasing hormone receptor on anterior pituitary somatotrophs activates a Gs protein pathway, raises cyclic AMP, and triggers release of stored growth hormone into the bloodstream. Because the analogue resists dipeptidyl peptidase-4, its plasma residence time exceeds that of native GHRH, producing a larger and more sustained secretory signal. The released growth hormone then acts on the liver and peripheral tissues to raise insulin-like growth factor 1, which feeds back on the hypothalamus and pituitary. This axis explains both the intended effects on fat distribution and the biological markers used to track them.
Studies of the compound rely on imaging and laboratory endpoints rather than on symptoms alone. Visceral adipose tissue is usually quantified by computed tomography or magnetic resonance imaging at the level of the abdomen, with waist circumference serving as a cheaper but less specific proxy. Blood work tracks insulin-like growth factor 1, fasting glucose, glycated hemoglobin, and lipid fractions. In the pivotal trials the imaging endpoint fell by roughly fifteen to twenty percent over six months, subcutaneous fat changed little, and the visceral fat returned toward baseline after treatment stopped, a pattern that shapes how clinicians discuss durability.
Because growth hormone is released in pulses, single measurements can misrepresent overall secretion. Investigators sometimes use repeated sampling or overnight profiles to capture the pattern rather than a single value. Provocative testing, in which a stimulus is given and the response is tracked over time, offers another way to characterize the axis. Each approach carries trade-offs between sensitivity, burden on the participant, and the influence of non-target variables.
Insulin-like growth factor 1 is produced largely in the liver in response to growth hormone signaling. Its concentration shifts over days rather than minutes, which makes it practical for tracking changes across a study period. Interpretation still depends on age, nutritional status, and concurrent illness, all of which independently affect the marker. Reference ranges are therefore stratified, and comparisons are usually made within an individual over time rather than against a single population threshold.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized cake in single-use vials |
| Solubility class | Freely soluble in water | Reconstituted with sterile diluent before injection |
| Typical storage temperature | 2 to 8 degrees Celsius | Before reconstitution; protect from light |
| Typical analytical method | Reversed-phase high-performance liquid chromatography | Purity and related-substance testing |
| Identity confirmation | Mass spectrometry | Observed mass near 5.1 kDa for the intact peptide |
Regulatory position depends on jurisdiction and on the form in which the material is sold. A branded product holds approval in the United States for a defined indication, and prescribing is confined to that label. Material marketed for laboratory research is not evaluated for human use and carries no such clearance. Independent verification therefore rests on certificates of analysis, third-party testing, and documented chain of custody. The substance also appears on the World Anti-Doping Agency prohibited list within the category covering growth hormone-releasing factors.
Lyophilized material is typically held under refrigeration between two and eight degrees Celsius, shielded from light and ambient moisture. Peptides of this size adsorb to glass and plastic, so working procedures often call for low-binding containers and as few transfers as possible. Absorbed water during weighing shifts the apparent mass of a sample, and controlling room humidity reduces that source of error. Once dissolved, solutions are kept cold and used within the interval printed on the accompanying label or certificate. Degradation accelerates markedly in dilute aqueous form.
Identity and purity are judged through a combination of chromatographic and mass spectrometric techniques. Reversed-phase high-performance liquid chromatography separates the intact peptide from truncated, oxidized, and deamidated variants, and the resulting peak-area percentages yield a purity figure. Electrospray ionization mass spectrometry confirms the expected molecular mass and can expose unanticipated modifications. Amino acid analysis and peptide mapping support sequence fidelity, while water content, pH, sterility, and bacterial endotoxin testing describe the physical and microbiological attributes of a finished lot.
=== Maximum-likelihood methods === The maximum-likelihood approach uses probability theory to complete all three steps simultaneously. It estimates critical parameters, including the divergence between sequences and the transition/transversion ratio, by deducing the most likely values to produce the input data.
In 2011, IUPAC evaluated the 2006 results of the Dubna–Livermore collaboration and concluded: "The three events reported for the Z = 118 isotope have very good internal redundancy but with no anchor to known nuclei do not satisfy the criteria for discovery". Because of the very small fusion reaction probability (the fusion cross section is ~0.3–0.6 pb or (3–6)×10−41 m2) the experiment took four months and involved a beam dose of 2.5×1019 calcium ions that had to be shot at the californium target to produce the first recorded event believed to be the synthesis of oganesson. Nevertheless, researchers were highly confident that the results were not a false positive, since the chance that the detections were random events was estimated to be less than one part in 100000. In the experiments, the alpha-decay of three atoms of oganesson was observed. A fourth decay by direct spontaneous fission was also proposed. A half-life of 0.89 ms was calculated: 294Og decays into 290Lv by alpha decay. Since there were only three nuclei, the half-life derived from observed lifetimes has a large uncertainty: 0.89+1.07−0.31 ms.
==== Expansion of molecular biology ==== In addition to the Division of Biology at Caltech, the Laboratory of Molecular Biology (and its precursors) at Cambridge, and a handful of other institutions, the Pasteur Institute became a major center for molecular biology research in the late 1950s. Scientists at Cambridge, led by Max Perutz and John Kendrew, focused on the rapidly developing field of structural biology, combining X-ray crystallography with Molecular modelling and the new computational possibilities of digital computing (benefiting both directly and indirectly from the military funding of science). A number of biochemists led by Frederick Sanger later joined the Cambridge lab, bringing together the study of macromolecular structure and function. At the Pasteur Institute, François Jacob and Jacques Monod followed the 1959 PaJaMo experiment with a series of publications regarding the lac operon that established the concept of gene regulation and identified what came to be known as messenger RNA. By the mid-1960s, the intellectual core of molecular biology—a model for the molecular basis of metabolism and reproduction— was largely complete. The late 1950s to the early 1970s was a period of intense research and institutional expansion for molecular biology, which had only recently become a somewhat coherent discipline. In what organismic biologist E. O. Wilson called "The Molecular Wars", the methods and practitioners of molecular biology spread rapidly, often coming to dominate departments and even entire disciplines.
== Later life == Dayhoff's Atlas became a template for many indispensable tools in large portions of DNA or protein-related biomedical research. In spite of this significant contribution, Dayhoff was marginalized by the community of sequencers. The contract to manage GenBank (a technology directly related to her research), awarded in 1983 by the NIH, went to Walter Goad at the Los Alamos National Laboratory. The reason for this attitude was unknown, with theories ranging from sexism to a clash of values with the experimental science community. Despite the success of Dayhoff's Atlas, experimental scientists and researchers considered their sequence information very valuable and were often reluctant to submit it to such a publicly available database. During the last few years of her life, she focused on obtaining stable, adequate, long-term funding to support the maintenance and further development of her Protein Information Resource. She envisioned an online system of computer programs and databases, accessible by scientists all over the world, for identifying protein from sequence or amino acid composition data, for making predictions based on sequences, and for browsing the known information. Less than a week before she died, she submitted a proposal to the Division of Research Resources at NIH for a Protein Identification Resource. After her death, her colleagues worked to make her vision a reality, and the protein database was fully operational by the middle of 1984.
== Overdose == Isoniazid causes seizure on overdose due to a depletion of pyridoxal 5′-phosphate (P5P) preventing glutamic acid decarboxylase from making gamma aminobutyric acid (GABA). Ordinary pyridoxine is an effective antidote of this mechanism of toxicity.
Sources: en.wikipedia.org
Christopher Richard Stein (born 4 January 1947) is an English celebrity chef, restaurateur, writer and television presenter. Along with business partner and first wife Jill Stein, he runs the Stein hotel and restaurant business in the UK. The business has a number of renowned restaurants, shops and hotels in Padstow along with other restaurants in Winchester and Barnes. He is the head chef and a co-owner of the Rick Stein at Bannisters restaurants in Mollymook and Port Stephens in Australia, with his second wife, Sarah. He writes cookery books and has presented numerous cookery series for the BBC.
== Further reading == Collip, James (May 1941). "Frederick Grant Banting, Discoverer of Insulin". The Scientific Monthly. 52 (5): 472–474. Bibcode:1941SciMo..52..472C. JSTOR 17312. Banting, F.G. & Best, C.H. (1922), "The Internal Secretions of the Pancreas", The Journal of Laboratory and Clinical Medicine, Vol.7, No.5, (February 1922), pp. 251–266. Banting, F.G., Best, C.H., Collip, J.B., Campbell, W.R. & Fletcher, A.A. (1922), "Pancreatic Extracts in the Treatment of Diabetes Mellitus", The Canadian Medical Association Journal, Vol.12, No.3, (March 1922), pp.141–146. US patent no.1,469,994 (held by "Frederick G. Banting and Charles Herbert Best, of Toronto, Ontario, and James Bertram Collip of Edmonton, Alberta, Canada"), (filed: 12 January 1923), (patented: 9 October 1923), for "Extract Obtainable from the Mammalian Pancreas or from the Related Glands in Fishes, Useful in the Treatment of Diabetes Mellitus, and a Method of Preparing it". Best, C. H. (November 1, 1942). "Frederick Grant Banting 1891–1941". Obituary Notices of Fellows of the Royal Society. 4 (11): 20–26. doi:10.1098/rsbm.1942.0003. S2CID 162239410. Bliss, Michael (1992) [1984]. Banting: A Biography. Toronto, Ontario: University of Toronto Press. ISBN 978-0-8020-7387-7. Banting, F. G.; Best, C. H. (2009). "The Journal of Laboratory and Clinical Medicine: Vol. VII St. Louis, February, 1922 No. 5". Nutrition Reviews. 45 (4): 55–57. doi:10.1111/j.1753-4887.1987.tb07442.x. PMID 3550540. Bliss, Michael (1990) [1982]. The Discovery of Insulin (3rd ed.). University of Toronto Press. ISBN 978-0-8020-8344-9.
== Proteolytic processing == Catechol oxidase is nuclear-encoded, and its N-terminal end contains a signal peptide that directs the protein to the chloroplast thylakoid lumen, where it can either be soluble or loosely associated with the thylakoid membrane. Initially transcribed as a pro-enzyme, the catechol oxidase precursor undergoes two rounds of proteolytic processing and transport before it enters the thylakoid lumen. Utilizing a [35S] methionine-labeled precursor protein, Sommer et al. elucidated a proteolytic processing pathway common to a variety of plants including pea (Pisum sativum), tomato (Lycopersicon esculentum), and maize (Zea mays). The 67 kD precursor was imported into the stroma in an ATP-dependent manner where a stromal peptidase processes the precursor into a 62 kD intermediate. The translocation of this intermediate into the thylakoid lumen was light-dependent and results in the generation of the mature 59 kD enzyme. Based on analysis of the precursor and mature catechol oxidase purified from Ipomoea batatas, proteolytic processing removes both the N-terminal transit peptide as well as a C-terminal domain that covers the enzyme active site.
== Prognosis == The long-term outlook (prognosis) for people with cold agglutinin disease varies based on many factors including the severity of the condition, the signs and symptoms present in each person and the underlying cause. For example, people with cold agglutinin disease caused by bacterial or viral infections tend to have an excellent prognosis; in these cases, the symptoms typically disappear within 6 months after the infection has resolved. Mild to moderate primary (unknown cause) cold agglutinin disease can also be associated with a good prognosis if excessive exposure to the cold is avoided. Those with cold agglutinin disease caused by HIV infection or certain types of cancer generally have a poor prognosis due to the nature of the underlying condition.
Relaxin family peptide hormones in humans are represented by seven members: three relaxin-like (RLN) and four insulin-like (INSL) peptides: RLN1, RLN2, RNL3, INSL3, INSL4, INSL5, INSL6. This subdivision into two classes (RLN and INSL) is based primarily on early findings, and does not reflect the evolutionary origins or physiological differences between peptides. For example, it is known that the genes coding for RLN3 and INSL5 arose from one ancestral gene, and INSL3 shares origin with RLN2 and its multiple duplicates: RLN1, INSL4, INSL6.
Sources: en.wikipedia.org
It mimics a natural hypothalamic signal that tells the pituitary to release growth hormone. The result is a rise in circulating growth hormone and, indirectly, in insulin-like growth factor 1. Over weeks of treatment this shift is associated with a selective decrease in fat stored inside the abdomen.
The primary measure is usually a cross-sectional abdominal scan that separates internal fat from fat just under the skin. Waist circumference and body weight are recorded as secondary measures because they are easy to obtain but do not distinguish the two fat compartments. Hormone and metabolic blood tests are collected alongside the imaging.
Available follow-up data indicate that visceral fat drifts back toward pretreatment levels once injections stop. The change is therefore best described as treatment-dependent rather than permanent. Investigators continue to debate whether intermittent or repeated courses would preserve any benefit.
It varies slowly and reflects cumulative axis activity rather than momentary secretion. Growth hormone is released in pulses affected by sleep, stress, and meals, making single readings hard to interpret. The slower marker gives a more stable picture across a study period.